Selank: The Calm Without the Cost
Last updated: March 2026
Selank is a synthetic heptapeptide developed at Russia's Institute of Molecular Genetics. A modified analog of tuftsin, it allosterically modulates GABA-A receptors — delivering anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or addiction risk. Approved in Russia since 2009.
GAD vs. benzodiazepine RCT
(not direct agonism)
Russia for anxiety
📋 On this page
How Selank Works
Selank operates through five overlapping neurochemical pathways. Unlike single-target drugs, this multi-system profile produces "clean" anxiolysis — calm clarity rather than sedated blunting.
Selank is a positive allosteric modulator of GABA-A receptors — the same receptor family targeted by benzodiazepines, but at a different binding site. Critically, it enhances GABAergic inhibition only in the presence of endogenous GABA, providing a built-in ceiling effect that prevents sedation and respiratory depression. Gene expression studies show 45 GABA-related genes altered within 1 hour of administration.
Selank inhibits enkephalin-degrading enzymes (enkephalinases), elevating plasma leu-enkephalin levels. Patients with generalized anxiety disorder exhibit shortened enkephalin half-life — Selank treatment significantly restored leu-enkephalin τ½ to normal values. Elevated endogenous opioids contribute to anxiolytic and mood-stabilizing effects (Sokolov et al., 2001, PMID: 11550013).
Selank influences serotonin, dopamine, and norepinephrine systems. Serotonergic effects contribute to mood stabilization; dopaminergic effects underlie the nootropic and psychostimulant qualities (cognitive enhancement beyond simple anxiety reduction). Meshavkin et al. (2006) confirmed dopamine and serotonin receptor modulation relevant to anxiety pathogenesis.
Selank upregulates BDNF mRNA expression in the hippocampus — a region central to emotional regulation and memory. Kolik et al. (2019, PMID: 31625062) showed Selank normalized pathologically elevated BDNF levels in rats during alcohol withdrawal and improved cognitive performance in aged non-alcoholic rats, suggesting neuroprotective activity.
As a tuftsin analog, Selank retains immunostimulatory properties. Yasenyavskaya et al. (2021) showed Selank normalized IL-1β, IL-6, TGF-β1, and TNF-α in a social stress model. Uchakina et al. (2008) demonstrated in vitro suppression of IL-6 gene expression in anxiety patients. Antiviral effects against influenza H3N2, HSV, and CMV have also been documented (Ershov et al., 2009).
Delivered intranasally, Selank accesses the brain via two routes: systemic absorption through nasal mucosa (bypassing first-pass metabolism) and direct olfactory nerve transport to the olfactory bulb — bypassing the blood-brain barrier entirely. Onset within 5–15 minutes; nasal bioavailability estimated at 70–90% for CNS-relevant delivery.
What the Research Shows
Evidence context: Selank has been approved and used clinically in Russia since 2009. It has a substantial peer-reviewed literature base spanning clinical RCTs, molecular pharmacology, and animal behavioral models going back to the early 1990s. The primary limitation is that most research is published in Russian journals with limited English translation, and no large-scale Western (FDA/EMA track) clinical trials exist.
How to Use Selank
Selank is primarily administered intranasally. The Russian approved formulation is a 0.15% solution (1.5 mg/mL). Research peptide vendors supply lyophilized powder for reconstitution. Subcutaneous injection is used in clinical research settings.
Intranasal Dosing (Primary Route)
| Experience Level | Daily Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 200–300 mcg | Once daily | Start here to assess individual sensitivity |
| Intermediate | 400–600 mcg | 1–2× daily | Most common therapeutic range in practice |
| Advanced / Protocol | 600–900 mcg | 2–3× daily | Weight-adjusted; based on clinical protocols |
| Russian Clinical Standard | ~450 mcg | 3× daily | 2 drops/nostril × 3× at 0.15% solution, 14-day course |
Weight-Based Intranasal Guide
| Body Weight | Men (mcg/day) | Women (mcg/day) | Frequency |
|---|---|---|---|
| Under 150 lbs | 200–400 | 150–300 | 1–2× daily |
| 150–200 lbs | 400–600 | 300–450 | 1–2× daily |
| 200+ lbs | 600–900 | 450–600 | 2–3× daily |
Cycling & Timing
Off: 1–2 weeks
Resume as needed. No documented tolerance requiring cycling, but recommended as best practice for receptor sensitivity.
🔄 Selank/Semax Rotation Protocol
Selank and Semax work through overlapping neurotransmitter systems, so running them back-to-back in a structured rotation — rather than simultaneously — is the approach favored by most experienced researchers. The standard cycle alternates three-week blocks of each compound with one-week breaks for receptor reset.
| Week | Compound | Dose | Route | Primary Effect |
|---|---|---|---|---|
| 1–3 | Selank | 200–400 mcg/day | Intranasal | Anxiolytic, mood stabilization |
| 4 | Break | — | — | Receptor sensitivity reset |
| 5–7 | Semax | 200–600 mcg/day | Intranasal | Focus, memory, neuroprotection |
| 8 | Break | — | — | Receptor sensitivity reset |
👃 Intranasal Administration Technique
- Tilt head slightly forward. Insert atomizer into one nostril and administer your dose.
- Wait 5–10 minutes before dosing the second nostril — this gives the nasal mucosa time to absorb before adding more volume.
- Avoid blowing your nose for at least 15 minutes after dosing. Clearing your sinuses too soon flushes the peptide before it can be absorbed.
- Stay upright for a few minutes post-administration to let the solution settle against the mucosal surface rather than draining immediately.
🧬 NA-Selank (N-Acetyl Selank Amidate)
The NA variant — N-Acetyl Selank Amidate — is a modified version of standard Selank with enhanced bioavailability at the nasal mucosa. The practical upshot: you need roughly 30–50% less to achieve equivalent effects compared to standard Selank. If you're dosing standard Selank at 300 mcg, start NA-Selank at 150–200 mcg and titrate from there. NA variants cost more per vial but can go further on a per-dose basis.
Side Effects & Safety
Selank has a well-documented favorable safety profile across three decades of Russian clinical use. Side effects are typically mild, transient, and primarily limited to the intranasal administration route.
Use with caution: Autoimmune disorders (theoretical immune perturbation risk) · Diabetics (monitor glucose) · Other GABAergic substances on same day until individual response established
Note: Selank does not impair psychomotor function, but assess personal response before operating heavy machinery
Selank vs. Pharmaceutical Anxiolytics
How does Selank stack up against the standard-of-care options for anxiety? The 2008 RCT (Zozulia et al.) directly compared Selank to medazepam in GAD patients. Here's the full picture.
Cross-trial caveat: Direct comparisons below draw from multiple study populations. Studies were conducted at different times, in different populations, and with different methods. Comparisons are conceptual — not head-to-head clinical trial data except where noted.
| Property | Selank | Benzodiazepines | SSRIs/SNRIs | Buspirone |
|---|---|---|---|---|
| Anxiolytic Efficacy | High (comparable to benzo in RCT) | High | Moderate–High | Moderate |
| Onset of Action | 15–30 min (intranasal) | 30–60 min | 2–6 weeks | 2–4 weeks |
| Sedation | None observed | Common | Possible | Minimal |
| Cognitive Impairment | None (may enhance cognition) | Common (amnesia, fog) | Possible | Minimal |
| Physical Dependence | Not documented | High — develops in days/weeks | Discontinuation syndrome | None |
| Withdrawal Syndrome | Not documented | Severe — potentially dangerous | Moderate (SSRI discontinuation) | None |
| Psychostimulant / Nootropic Effect | Yes — antiasthenic, pro-cognitive | No — cognitive blunting | No | No |
| Immunomodulation | Yes — anti-inflammatory, antiviral | None / immunosuppressive | None significant | None |
| Regulatory Status (Russia) | Approved 2009 ✓ | Approved | Approved | Approved |
| Regulatory Status (USA) | Research compound only | Schedule IV (controlled) | FDA approved | FDA approved |
Who Researches Selank?
✓ This Research Is Relevant If You...
- Experience generalized anxiety, worry, or rumination and want alternatives to benzodiazepines
- Need to reduce stress reactivity without cognitive blunting or sedation
- Want something that works within 15–30 minutes for acute anxiety situations
- Are interested in nootropic + anxiolytic combinations — Selank may enhance focus alongside anxiety reduction
- Want to avoid physical dependence risk inherent to benzodiazepines
- Have burnout with a fatigue component — antiasthenic effects address both anxiety and energy deficit
- Are exploring Russian-developed neuropeptides as a research area
- Want immune system support as a side benefit of an anxiolytic compound
✗ This Research May Not Apply If You...
- Require FDA-approved anxiety treatments — Selank is not available as a pharmaceutical in the US or EU
- Want oral medications — Selank requires intranasal or subcutaneous administration
- Need extensive Western clinical trial data before considering a compound
- Are pregnant or breastfeeding — no safety data exists for these populations
- Have an active autoimmune condition — theoretical immune modulation risk
- Are primarily seeking a cognitive boost without anxiolytic effects — Semax may be more appropriate
Primary Research Sources
Key Takeaways
- Anxiolytic effects comparable to benzodiazepines in 62-patient RCT (Zozulia 2008)
- Positive allosteric GABA-A modulator — not a direct agonist, so no sedation ceiling breach
- No sedation, cognitive impairment, dependence, or withdrawal in clinical studies
- Adds antiasthenic + psychostimulant effects absent in benzodiazepines
- Approved in Russia since 2009 with three decades of research
- Immunomodulatory via tuftsin heritage — normalizes stress-induced cytokine dysregulation
- Upregulates BDNF in hippocampus — potential neuroprotective properties
- Onset within 15–30 min intranasal — usable for acute anxiety situations
- No FDA/EMA approval — zero Western clinical trials
- Most data from Russian institutions with limited English translation
- Exact GABA-A binding site geometry still under investigation
- Long-term safety data (years of continuous use) not established
- N-Acetyl Selank Amidate is more potent but has less clinical research behind it
- Interaction data with psychiatric medications is very limited
- Effects in autoimmune populations require caution — immune system may be unpredictably affected
🔬 Verified Research Source
Third-party tested research compounds from Swiss Chems — lab certificates of analysis included with every order.
Affiliate links — supports HighPeptides research content at no extra cost. All Swiss Chems products include third-party CoA.
🛒 Recommended Products
Supplies for intranasal peptide use — reconstitution, administration, and storage.
Affiliate links help support HighPeptides at no extra cost to you.
Related Compounds & Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Selank is NOT FDA approved in the United States or approved by the EMA in the European Union. It is approved in Russia for anxiety and neurasthenia. This page is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Approved Russia 2009Research Compound — US/EU